000			03759nam a22003735i 4500
001			233026
003			ES-VaUE
005			20221220020434.0
007			cr nn 008mamaa
008			200831s2020 xxu| s |||| 0|eng d
020			_a9781071607718
024	7		_a10.1007/978-1-0716-0771-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aGapmers _bMethods and Protocols _cedited by Toshifumi Yokota, Rika Maruyama.
250			_a1st edition 2020
264		1	_aNew York, NY _bSpringer International Publising _c2020
300			_a1 recurso en línea (XI, 247 páginas) _b39 ilustraciones, 29 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v2176
505	0		_aInvention and Early History -- Development and Clinical Applications of Antisense Oligonucleotide Gapmers -- Knocking Down Long Non-coding RNAs using Antisense Oligonucleotide Gapmers -- Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease -- Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy -- Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis -- Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides -- DNA/RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing -- Tips for Successful lncRNA Knockdown using Gapmers -- Calcium-Mediated In Vitro Transfection Technique of Oligonucleotides with Broad Chemical Modification Compatibility -- Evaluating the Knockdown Activity of MALAT1 ENA Gapmers in vitro -- Albumin-binding Fatty Acid-modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics -- The use of Gapmers for in vivo Suppression of Hepatic mRNA Targets -- Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/ FTD Caused by the C9orf72 Repeat Expansion -- Targeted Gene Silencing in Malignant Hematolymphoid Cells using GapmeR -- Gapmer Antisense Oligonucleotides to Selectively Suppress the Mutant allele in COL6A Genes in Sominant Ullrich Congenital Muscular Dystrophy -- Detection of Locked Nucleic Acid Gapmers from Mouse Samples using ELISA.
520			_aThis volume presents a comprehensive collection of detailed state-of-the-art protocols for gapmer-mediated RNA knockdown from leaders in the field. Chapters detail a historical and contemporary perspective of RNase H-inducing antisense oligonucleotides called gapmers and gapmer-mediated RNA knockdown for basic research and therapies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Gapmers: Methods and Protocols aims to provide diverse applications of gapmers along with protocols that will assist readers in moving the frontier.
700	1		_aYokota, Toshifumi _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMaruyama, Rika _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781071607701
776	0	8	_iPrinted edition: _z9781071607725
776	0	8	_iPrinted edition: _z9781071607732
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-0716-0771-8 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_2020
999			_c233026 _d233026